SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: Chess Master, GREGG THE GREEK
Search This Board: 
Last Post: 3/22/2017 2:41:51 AM - Followers: 72 - Board type: Free - Posts Today: 1

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
GALT News: Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 03/21/2017 08:30:00 AM
GALT News: GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema) 03/14/2017 08:47:34 AM
GALT News: Current Report Filing (8-k) 03/14/2017 08:23:00 AM
GALT News: Galectin Therapeutics to Present at 29th Annual ROTH Conference 03/09/2017 08:30:00 AM
GALT News: Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis 03/06/2017 08:30:00 AM
PostSubject
#2969   The Stock performed well despite the massive selloff. Chess Master 03/22/17 02:41:51 AM
#2968   This looks very promising Hotp0ckets 03/21/17 12:04:23 AM
#2967   Keep it coming. Genie2016 03/20/17 11:10:07 PM
#2966   Acquisitions at rich values http://www.businesswire.com/news/home/20151006005893 goingforittoday 03/20/17 08:57:10 PM
#2962   I am in agreement after digging more and Tekterra 03/20/17 12:05:06 PM
#2961   I appreciate biotech2010's willingness to share his/her views. Darwinian 03/20/17 09:52:41 AM
#2959   I have been a GALT shareholder for 8 biotech2010 03/20/17 01:05:55 AM
#2957   They don't have nearly enough data to convince biotech2010 03/19/17 08:03:04 PM
#2956   IMO this company is vastly undervaled Hotp0ckets 03/19/17 07:37:39 PM
#2955   What specifically ? GREGG THE GREEK 03/19/17 06:52:36 PM
#2954   Chart wise, I like what I'm seeing GREGG THE GREEK 03/19/17 06:52:00 PM
#2953   Been digging into the info myself. GREGG THE GREEK 03/19/17 06:51:05 PM
#2952   I believe so GREGG THE GREEK 03/19/17 06:48:47 PM
#2951   It sounds like they may target extreme forms. gss2003 03/19/17 05:39:16 PM
#2950   Read slide 69 thanks and came to the Chess Master 03/19/17 04:47:04 PM
#2949   I think you have a really good grasp Chess Master 03/19/17 03:45:22 PM
#2948   Per your post, don't you think you're a Genie2016 03/19/17 02:15:01 PM
#2946   Those of you dreaming about a partnership with biotech2010 03/19/17 01:57:23 PM
#2945   OMG, I love this stock. Genie2016 03/19/17 01:55:51 PM
#2944   Keep the faith alive. Genie2016 03/19/17 01:54:53 PM
#2943   Already strike first inning nicely. Genie2016 03/19/17 01:54:03 PM
#2942   It's going to be a hit! Genie2016 03/19/17 01:53:03 PM
#2941   Relative strength breakout as of yesterday! Bullish! sokol 03/17/17 09:42:52 AM
#2940   Yup nice cross of the 50 and 200 RyGuy 03/17/17 09:32:19 AM
#2939   Look at the technicals they are ripe for Chess Master 03/17/17 04:25:52 AM
#2938   That makes sense to me. A take Tekterra 03/15/17 03:35:20 PM
#2937   Here's my stream of consciousness on the current topic. IRAHopeful 03/15/17 03:05:23 PM
#2936   When you put it that way with a Tekterra 03/15/17 02:39:42 PM
#2935   You really don't have a clue about this company. biotech2010 03/15/17 01:03:00 AM
#2934   If they do a partnership that finds Skin gss2003 03/14/17 06:09:14 PM
#2933   If any negotiations are going on I doubt Tekterra 03/14/17 06:05:11 PM
#2932   Good point. Unless they get a great offer gss2003 03/14/17 05:36:43 PM
#2931   Good point. Unless they get a great offer gss2003 03/14/17 05:36:42 PM
#2930   This thing popped because of institutional accumulation. Tekterra 03/14/17 04:50:05 PM
#2929   They do have a billionaire backing them. Tekterra 03/14/17 04:46:50 PM
#2928   This thing pops more on technicals and sentiment Coolec78 03/14/17 11:58:33 AM
#2927   http://www.conferencecalltranscripts.org/8/summary/?id=3588010 Coolec78 03/14/17 08:59:14 AM
#2926   Golden Cross about to occur... RyGuy 03/13/17 12:02:28 PM
#2925   It works either way, isn't it? Coolec78 03/10/17 05:57:47 PM
#2924   :))))))))) Coolec78 03/10/17 05:56:03 PM
#2923   I think you meant to say, "Let's hope thefamilyman 03/10/17 05:45:04 PM
#2922   Let's hope his ego is as big as Coolec78 03/10/17 05:25:11 PM
#2921   Nice move on GALT RyGuy 03/10/17 11:43:59 AM
#2920   I agree completely-Traber is an egomaniac who won't biotech2010 03/09/17 03:00:27 PM
#2919   You are Crazy - No way - Traber Chess Master 03/09/17 12:53:03 PM
#2918   Good read. RyGuy 03/09/17 10:18:00 AM
#2917   Really good article. lot of info, lot of Coolec78 03/08/17 12:29:49 AM
#2916   Article by the same aurthor from SA: jmh0602 03/07/17 06:58:13 PM
#2915   Not sure but this would seem to be Arrowhead58 03/06/17 03:01:32 PM
#2914   GILD or MRK? jmh0602 03/06/17 12:50:35 PM
PostSubject